Cytotoxic mannich bases of 1-arylidene-2-tetralones.
Various 1-arylidene-2-tetralones 1 had been shown previously to possess moderate cytotoxic properties unaccompanied by murine toxicity. The objective of the present investigation was to undertake different molecular modifications of representative members of series 1 with a view to discerning those structural features leading to increased potencies. All compounds were evaluated using human Molt 4/C8 and CEM T-lymphocytes as well as murine P388 and L1210 leukemic cells. The Mannich bases 2, 4, 5 and 7 possessed increased potencies compared to the corresponding unsaturated ketones 1 and in general were potent cytotoxics having IC50 values in the 0.2-10 microM range. QSAR using the cytotoxicity data for 2a-e suggested that potency was positively correlated with the size of the substituents in the arylidene aryl ring. Compounds 2a-f were evaluated using a panel of approximately 53 human tumour cell lines and, when all cell lines were considered, were more potent than the reference drug melphalan. In particular, marked antileukemic activity was displayed. Molecular modeling was utilized in order to evaluate whether the shapes of the different compounds contributed to the varying potencies observed. Representative compounds demonstrated minimal or no inhibiting properties towards human N-myristoyltransferase (NMT) and did not bind to calf thymus DNA. This study has revealed a number of unique lead molecules as candidate anti-neoplastic agents serving as prototypes for future development.
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada. dimmock@skyway.usask.ca
J R
JR
Dimmock
M P
MP
Padmanilayam
U
U
Das
G A
GA
Zello
R K
RK
Sharma
A
A
Shrivastav
P
P
Selvakumar
M K
MK
Pasha
K H
KH
Nienaber
J S
JS
Lee
T M
TM
Allen
C L
CL
Santos
J
J
Balzarini
E
E
De Clercq
D000217:Acyltransferases / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity*; D045744:Cell Line, Tumor; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D015458:Leukemia, T-Cell / Q000188:drug therapy; D008352:Mannich Bases / Q000138:chemical synthesis / Q000737:chemistry; D051379:Mice; D010880:Piperidines / Q000737:chemistry; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000187:drug effects; D044024:Tetralones / Q000737:chemistry* / Q000633:toxicity*
D000970:Antineoplastic Agents; D008352:Mannich Bases; D010880:Piperidines; D044024:Tetralones; D000217:Acyltransferases; C050480:glycylpeptide N-tetradecanoyltransferase